Dengvaxia (Dengue vaccine) / Sanofi - LARVOL DELTA

Dengue Vaccine Effectiveness: Results from a 6-Year Population-Based Cohort Study in Southern Brazil. (PubMed, Am J Trop Med Hyg) - "Vaccination with at least one dose was associated with approximately a one-third reduction in PDC incidence and a significant reduction in DENV-1 and DENV-4 cases. Despite the VE falling below 50%, vaccination may be justifiable in regions with high disease burden."

Journal • Dengue Fever

Animal Models Illuminate Dengue Immunopathogenesis to Guide Vaccine and Therapeutic Developments. (PubMed, J Virol Methods) - "The protection provided by the monoclonal antibody C10 was shown to mitigate antibody-dependent enhancement (ADE) in murine models, though it is not associated with the Dengvaxia vaccine. The further development of these animal models will be necessary to expedite the safe development of next-generation dengue vaccines (TAK-003, TV003/TV005), antivirals (favipiravir, sofosbuvir), and immune modulators (IL-6 and TNF-α blockers) for use in endemic areas."

Journal • Preclinical • Review • Dengue Fever • Hematological Disorders • Infectious Disease • Obesity • IFNAR2 • IL1B • IL6

Dengue Incidence Following Mass Vaccination: An Interrupted Time Series Study in Paraná, Brazil. (PubMed, Trop Med Infect Dis) - "The campaign was more effective in small municipalities since they had higher vaccination coverage. These findings underscore the significant impact of the vaccination campaign on reducing dengue incidence trends across the targeted municipalities."

Journal • Dengue Fever

Barriers to dengue vaccine coverage in low- and middle-income countries (LMICs). (PubMed, Virology) - "Dengvaxia (CYD-TDV) and Qdenga (TAK-003) are the only two licensed dengue vaccines currently available, while Butantan-DV (TV003) is an advanced candidate with promising Phase 3 clinical trial results...We therefore identify several state and market-driven systemic factors, as well as declining vaccine confidence, as barriers to scaling up dengue vaccine access in LMICs. These barriers must be addressed through creative solutions to ensure the equitable distribution of dengue vaccines to the populations and countries that need them the most."

Journal • Review • Dengue Fever • Infectious Disease

Bridging the knowledge gap: Thai parents' perspectives on dengue infection and its vaccination and the need for targeted promotion. (PubMed, PLoS Negl Trop Dis) - "This study provides insights into Thai parents' understanding of dengue and its vaccine in children. Findings offer a basis for developing targeted public health campaigns and communication strategies to promote dengue vaccine use in children, and to inform public policy on vaccine affordability."

Journal • Dengue Fever • Infectious Disease

Current status of dengue fever epidemics and vaccine development. (PubMed, Virol Sin) - "To date, two vaccines-Dengvaxia and Qdenga-have been licensed for clinical use. Six other vaccine candidates are currently in clinical trials, among which the tetravalent live-attenuated vaccines TV003/TV005 are considered the most promising. Despite considerable advances in dengue vaccine research, significant challenges remain, including the need to elicit balanced immune responses against the four serotypes and to reduce the risk of antibody-dependent enhancement (ADE). Taken together, this review systematically summarizes recent global and regional trends in dengue fever and the current progress in dengue vaccine development, collectively offering a valuable resource for informing prevention and control strategies."

Journal • Review • Dengue Fever • Infectious Disease

Preclinical evaluation of DENV1 mRNA vaccines in mice: Toward improved neutralizing antibody and T cell responses. (PubMed, Biomed Pharmacother) - "Currently, licensed vaccines, Dengvaxia® and Qdenga®, rely on live-attenuated platforms but show limited efficacy due to imbalanced immune responses and risks associated with antibody-dependent enhancement (ADE)...However, the prJEV chimera exhibited low immunogenicity, likely due to prM-E domain incompatibility. Overall, the WT prME construct showed the most favorable balance of immunogenicity and safety, supporting its advancement as a prototype for future tetravalent dengue mRNA vaccine development."

Journal • Preclinical • CNS Disorders • Dengue Fever • Infectious Disease

Optimizing Humoral Immunity for Durable and Broad Protection in Flavivirus Vaccines. (PubMed, Vaccines (Basel)) - "Booster scheduling and baseline serostatus further shape the antibody quality, highlighting the importance of immune imprinting and cross-reactivity in vaccine design. Together, these findings outline the design principles for next-generation flavivirus vaccines, including stabilization of neutralization-sensitive epitopes, use of adjuvants that sustain germinal center responses, optimization of antigen persistence, and tailoring of dosing strategies to immune history to elicit durable and broadly protective humoral immunity."

Journal • Review • CNS Disorders • Dengue Fever • Infectious Disease

Targeting Dendritic Cells with Virus-like Particles: Toward Safer and More Immunogenic Vaccines. (PubMed, Vaccines (Basel)) - "The newer "Qdenga" vaccine offers up to 80% efficacy after a year but provides suboptimal protection against DENV-3 in seronegative individuals... The administration of tetravalent dengue VLP vaccine in BALB/c mice did not result in adverse effects in acute or chronic toxicity evaluations. Therefore, the VLP supports progression toward clinical evaluation, with dendritic cell activation providing additional rationale."

Journal • Dengue Fever • Hematological Disorders

Dengue vaccine effectiveness and safety: a systematic analysis of recent clinical trial data. (PubMed, Virol J) - "This review provides a systematic review of the dengue vaccines data available from the last five years highlighting significant progress in vaccine development, efficacy, and safety and TAK-003 showed the greatest efficacy against hospitalized and symptomatic Dengue patients, reducing risk by 85% (RR 0.15; 95% CI 0.07-0.33)."

Journal • Review • Dengue Fever • Infectious Disease

Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18-50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial. (PubMed, Hum Vaccin Immunother) - P2 | "None of the participants discontinued the study due to an AE, and no deaths were reported. CYD-TDV demonstrated adequate safety and robust immunogenicity against all dengue serotypes in HIV-positive adults receiving prior antiretroviral treatment."

Journal • P2 data • Dengue Fever • Human Immunodeficiency Virus • Infectious Disease • Pain

Global epidemiology of dengue in paediatric and adolescent populations: a systematic review and meta-analysis. (PubMed, Infect Dis (Lond)) - "Dengue infection affects youth globally across all endemic regions, with similar incidence distribution among continents. These findings illuminate the global and country-specific dengue epidemiology, emphasising the need for enhanced mitigation measures to reduce viral spread and impact."

Journal • Retrospective data • Dengue Fever • Infectious Disease • Pediatrics

Assessing the impact of vaccination against dengue viruses using long-term antibody measurements (ASTMH 2025) - "The results suggest that the vaccine's protection is skewed towards a single dominant serotype, and this protection is of shorter duration compared to natural infection. These preliminary findings align with previous evidence suggesting that Dengvaxia's effectiveness may be limited by immunodominance and interference."

Dengue Fever • Infectious Disease

Challenges in the Prevention and Treatment of Dengue Fever: An Emerging Issue. (PubMed, Am J Trop Med Hyg) - "Existing vaccines, such as Dengvaxia® (Sanofi Pasteur, Paris, France) and Qdenga® (Takeda Pharmaceutical Company, Tokyo, Japan), have demonstrated some efficacy; however, limitations include a lack of efficacy against certain regional DENV strains and the potential for antibody-dependent enhancement (ADE), particularly in individuals without previous DENV exposure...The intricate pathogenesis of DENV, involving complex virus-host interactions and immune responses, presents additional treatment challenges. In this review, the current challenges and advancements in DF prevention and treatment are examined, emphasizing the limits of existing vaccines and medicines while exploring novel approaches with potential for effectiveness in clinical settings."

Journal • Dengue Fever

Structural and energetic basis of marine phytochemicals as dengue NS1 protein inhibitors. (PubMed, Sci Rep) - "It may suppress DENV proliferation. QSAR study suggested that this chemical is anti-viral, although in vivo and in vitro testing is needed."

Journal • Dengue Fever • Infectious Disease

Pathophysiology and clinical implications of dengue-associated neurological disorders. (PubMed, Front Microbiol) - "Although there are still challenges in reaching the ideal vaccination coverage, the introduction of potent vaccines like Dengvaxia and Qdenga provide an achievable option for prevention. Thorough study into DENV's neurological effects and treatment options is essential as the virus's geographic range is increased by climate change and international travel. Reducing the worldwide burden of dengue-related neurological complications requires addressing the intricate interactions between virological, immunological, and environmental variables."

Journal • Review • CNS Disorders • Dengue Fever • Infectious Disease • Inflammation • Multiple Sclerosis • Pain

Afucosylation of anti-dengue IgG is associated with enhanced susceptibility to dengue virus infection postvaccination. (PubMed, Sci Transl Med) - "Together, these findings support a model in which the presence of afucosylated IgG promotes virus replication, increasing the likelihood of productive infection upon DENV exposure. Moreover, these results highlight that IgG1 fucosylation is a predictor of risk for breakthrough DENV infection despite vaccination and support the importance of investigating strategies to regulate Fc fucosylation during vaccination."

Journal • Dengue Fever • Infectious Disease

State of the Art on Vaccine Development Against Dengue Infection: Scoping Review of the Literature. (PubMed, Infect Dis Rep) - "Vaccines were categorized into licensed (CYD-TDV and TAK-003), late-stage (TV003/TV005), and early-stage candidates (TDEN, DPIV, V180, TVDV)...TAK-003 (Qdenga®) demonstrated high efficacy against virologically confirmed dengue (VCD) and dengue-related hospitalization...Currently, TAK-003 is regarded as the best option for broad implementation, while TV003 and TV005 remain promising candidates due to their shorter schedule and robust immunogenicity. Further research is needed to optimize vaccine strategies in seronegative populations, immunocompromised subjects, older adults, and travelers."

Journal • Review • Dengue Fever • Infectious Disease

A retrospective computational validation of a clinically evaluated recombinant envelope protein tetravalent dengue vaccine. (PubMed, Int J Biol Macromol) - "Licensed vaccines like Dengvaxia and Qdenga rely on yellow fever virus (YFV)-based vectors encoding DENV structural proteins, though ADE risks persist. However, limitations in predictive accuracy were noted, such as the erroneous docking of EDE1-C10 to EDIII, highlighting the need for improved modeling approaches incorporating structural dynamics and artificial intelligence (AI) tools. These results support further development of V180 and r2ED, while emphasizing the strengths and boundaries of computational vaccinology."

Journal • Retrospective data • Dengue Fever • Infectious Disease • CD8

Advancing dengue vaccine development: Challenges, innovations, and the path toward global protection. (PubMed, Pediatr Investig) - "This review provides a comprehensive analysis of the historical and current landscape of dengue vaccine development, focusing on CYD-TDV, TAK-003, and Butantan-DV...Additionally, this review highlights key areas for future research, including the impact of ADE, advancements in vaccine platforms, the need for region-specific vaccine formulations, and the integration of vaccination into broader dengue prevention strategies. Ultimately, sustained investment and global collaboration are crucial for achieving the goal of a dengue-free world."

Journal • Review • Dengue Fever

The pre- and post-COVID-19 pandemic dengue fever patterns in southeastern coastal China in 2019 and 2024: molecular evolution and strain replacement. (PubMed, Front Microbiol) - "Complete genotype turnover of DENV-1 occurred in southeastern coastal China between 2019 and 2024, driven by displacement of lineage 1I_E.1 by 1I_K.2, with implications for local transmission patterns. Observed antigenic divergence between temporal isolates emphasizes the importance of sustained genomic monitoring and targeted intervention strategies tailored to circulating strains in this region."

Journal • Dengue Fever • Infectious Disease • Novel Coronavirus Disease

CYD00082: Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia (clinicaltrials.gov) - P=N/A | N=918 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Trial completion date: Jan 2030 ➔ Jul 2028 | Trial primary completion date: Jan 2030 ➔ Jul 2028

Trial completion date • Trial primary completion date • Dengue Fever

Dengue Vaccines. (PubMed, Curr Top Microbiol Immunol) - "The chapter reviews the historical trajectory and current landscape of vaccine candidates, such as Dengvaxia®, Qdenga®, and Butantan-DV, analyzing their efficacy, safety profiles, and the lessons learned from their clinical trials. It also discusses other hurdles like suitable animal models and viral interference. Ultimately, the chapter highlights the advancements made and outlines future research directions crucial for a universally effective dengue vaccine."

Journal • Dengue Fever

Medical knowledge, political tension, and social relevance: a content and framing analysis of vaccine-related TV broadcasts in the Philippines. (PubMed, BMJ Public Health) - "Training health professionals to emphasise under-represented information and to purposively engage with prominent message frames could improve vaccination communication. Beyond vaccine hesitancy, our results also highlight how methodological advances can guide public health stakeholders analysing societal discourses and seeking to convey medical information to the broader population."

Journal • Developmental Disorders • Infectious Disease • Novel Coronavirus Disease

From controversy to confidence: Strengthening dengue vaccines safety reporting. (PubMed, Vaccine) - "Dengue vaccines-Dengvaxia, Qdenga, and TV003/TV005 (NIH dengue vaccine) -offer potential for control, yet their implementation has been challenged by safety issues, including heightened risks in seronegative individuals, presumably due to antibody-dependent enhancement, though the precise mechanisms remain under investigation...The erosion of public trust following past vaccine controversies highlights the urgent need for transparency to bolster acceptance and inform policy. By integrating advanced surveillance with international cooperation, these measures can refine risk-benefit assessments, rebuild confidence in immunization programs, and maximize the protective impact of dengue vaccines, ultimately reducing the burden on vulnerable populations worldwide."

Journal • Dengue Fever